[1]来佳成,韩永生.脂蛋白磷脂酶A2、非高密度胆固醇与颈动脉粥样硬化程度的相关性研究[J].医学信息,2021,34(09):115-118.[doi:10.3969/j.issn.1006-1959.2021.09.030]
 LAI Jia-cheng,HAN Yong-sheng.Study on the Correlation Between Lipoprotein Phospholipase A2,Non-high-density Cholesterol and the Degree of Carotid Atherosclerosis[J].Medical Information,2021,34(09):115-118.[doi:10.3969/j.issn.1006-1959.2021.09.030]
点击复制

脂蛋白磷脂酶A2、非高密度胆固醇与颈动脉粥样硬化程度的相关性研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年09期
页码:
115-118
栏目:
论著
出版日期:
2021-05-01

文章信息/Info

Title:
Study on the Correlation Between Lipoprotein Phospholipase A2,Non-high-density Cholesterol and the Degree of Carotid Atherosclerosis
文章编号:
1006-1959(2021)09-0115-04
作者:
来佳成韩永生
(安徽医科大学附属省立医院急救医学中心,安徽 合肥 230001)
Author(s):
LAI Jia-chengHAN Yong-sheng
(Emergency Medicine Center,Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,Anhui,China)
关键词:
脂蛋白磷脂酶A2非高密度脂蛋白胆固醇颈动脉粥样硬化
Keywords:
Lipoprotein phospholipase A2Non-high-density lipoprotein cholesterolCarotid atherosclerosis
分类号:
R543.4
DOI:
10.3969/j.issn.1006-1959.2021.09.030
文献标志码:
A
摘要:
目的 研究脂蛋白磷脂酶A2、非高密度脂蛋白胆固醇与颈动脉粥样硬化程度的关系,探索Lp-PLA2联合non-HDL-C预测颈动脉粥样硬化程度的应用价值。方法 回顾性分析2019年10月~2020年4月就诊于中国科学技术大学附属第一医院急救中心,并同时行Lp-PLA2检测和颈动脉评估的患者226例临床资料,根据颈动脉评估情况分为对照组(n=58)、轻度病变组(n=118)、重度病变组(n=50),比较各组一般资料、Lp-PLA2、non-HDL-C水平,分析Lp-PLA2与non-HDL-C的相关性。结果 病变组与对照组糖尿病、高同型半胱氨酸、肾功能不全占比比较,差异有统计学意义(P<0.05),轻度病变组与重度病变组比较,差异无统计学意义(P>0.05);三组间Lp-PLA2、non-HDL-C、斑块计数两两比较,差异有统计学意义(P<0.05);线性相关分析结果显示, Lp-PLA2与non-HDL-C呈线性相关(r=0.465,P<0.001)。结论 Lp-PLA2、non-HDL-C与颈动脉粥样硬化程度显著相关,提示两者可用于颈动脉动脉粥样硬化程度的预测,进一步提升评价效果的可靠性。
Abstract:
Objective To study the relationship between lipoprotein phospholipase A2, non-high-density lipoprotein cholesterol and the degree of carotid atherosclerosis, and explore the application value of Lp-PLA2 combined with non-HDL-C in predicting the degree of carotid atherosclerosis. Methods A retrospective analysis of the clinical data of 226 patients in the emergency center of the First Affiliated Hospital of the USTC from October 2019 to April 2020, and who underwent Lp-PLA2 detection and carotid artery assessment, were retrospectively analyzed.According to the assessment of carotid artery, they were divided into control group (n=58), mild disease group (n=118), and severe disease group (n=50).The general data, Lp-PLA2, non-HDL-C levels of each group were compared, and the correlation between Lp-PLA2 and non-HDL-C was analyzed.Results There was a statistically significant difference in the proportion of diabetes, high homocysteine, and renal insufficiency between the diseased group and the control group (P<0.05).There was no statistically significant difference between the mild disease group and the severe disease group (P>0.05);Pairwise comparisons of Lp-PLA2, non-HDL-C, and plaque counts among the three groups showed statistically significant differences (P<0.05);The results of linear correlation analysis showed that Lp-PLA2 was linearly correlated with non-HDL-C (r=0.465,P<0.001).Conclusion Lp-PLA2 and non-HDL-C are significantly related to the degree of carotid atherosclerosis, suggesting that both can be used to predict the degree of carotid atherosclerosis, and further improve the reliability of the evaluation effect.

参考文献/References:

[1]Kelly BB,Narula J,Fuster V.Recognizing global burden of cardiovascular disease and related chronic diseases[J].Mt Sinai J Med,2012,79(6):632-640. [2]陈伟伟,高润霖,刘力生,等.《中国心血管病报告_2017》概要[J].中国循环杂志,2018,33(1):1-8. [3]Alenghat FJ,Davis AM.Management of Blood Cholesterol[J].JAMA,2019,321(8):800-801. [4]Steen DL,Khan I,Ansell D,et al.Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence(NICE)2014 lipid modification guidelines[J].BMJ Open,2017,7(2):e13255. [5]Catapano AL,Graham I,De Backer G,et al.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias[J].Eur Heart J,2016,37(39):2999-3058. [6]Grundy SM,Stone NJ,Bailey AL,et al.2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Circulation,2019,139(25):e1082-e1143. [7]Maiolino G,Bisogni V,Rossitto G,et al.Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications[J].World Journal of Cardiology(WJC),2015(10):609-620. [8]Kheirandish-Gozal L,Philby MF,Qiao Z,et al.Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein‐Associated Phospholipase A2 Plasma Activity Levels[J].Journal of the American Heart Association,2017,6(2):e004923. [9]Abajobir AA,Abate KH,Abbafati C,et al.Global,Regional,and national comparative risk assessment of 84 behavioural,environmental and occupational,and metabolic risks or clusters of risks,1990-2016:asystematic analysis for the global burden of disease study 2016[J].Lancet,2017,390(10100):1345-1422. [10]Beaglehole R,Bonita R.Global public health:a scorecard[J].Lancet,2008,372(9654):1988-1996. [11]杜文婷,刘萍.颈动脉超声检测在心脑血管疾病中的应用概况[J].中西医结合心脑血管病杂志,2016,14(10):1117-1120. [12]Koskinen JS,Kyto V,Juonala M,et al.Childhood risk factors and carotid atherosclerotic plaque in adulthood: The Cardiovascular Risk in Young Finns Study[J].Atherosclerosis,2020(293):18-25. [13]Thompson A,Gao P,Orfei L,et al.Lipoprotein-associated phospholipase A(2)and risk of coronary disease, stroke, and mortality:collaborative analysis of 32 prospective studies[J].Lancet,2010,375(9725):1536-1544. [14]Pencina KM,Thanassoulis G,Wilkins JT,et al.Trajectories of Non-HDL Cholesterol Across Midlife:Implications for Cardiovascular?Prevention[J].J Am Coll Cardiol,2019,74(1):70-79.

相似文献/References:

[1]李 靖.非高密度脂蛋白胆固醇与心脑血管疾病的关系研究[J].医学信息,2022,35(12):100.[doi:10.3969/j.issn.1006-1959.2022.12.024]
 LI Jing.Study on the Relationship Between Non-high Density Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Diseases[J].Medical Information,2022,35(09):100.[doi:10.3969/j.issn.1006-1959.2022.12.024]

更新日期/Last Update: 1900-01-01